{"changes":[],"country":"US","description":"Syremis Therapeutics is a Tel Aviv clinical-stage biotech developing oral small molecules for schizophrenia, depression, and other psychiatric disorders. Lead drug ST-905, a once-daily M1/M4 muscarinic agonist, is in Phase 1. Co-founded by the team behind Karuna's Cobenfy and launched with a $165M Series A.","domain":"syremisrx.com","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":42.358834,"lng":-71.05783,"location":"Boston MA","name":"Syremis Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":165000000,"currency":"USD","date":"2025-08-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"syremisrx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"syremisrx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://syremisrx.com"},{"fact":"description","publisher":"syremisrx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://syremisrx.com"}],"stage":"series-a","techStack":[],"totalRaisedUsd":165000000,"updatedAt":"2026-05-07"}